A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

NCT02670044 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG: Cobimetinib
DRUG: Idasanutlin
DRUG: Venetoclax

Sponsor

Hoffmann-La Roche